Who Paid My Doc
Craig Laforce
Allergy & Immunology Raleigh, NC Medical Doctor
NPI 1922005727 CMS profile 314247
2615 Lake Dr, Suite 301, Raleigh, NC 27607
General payments
$14,108
Research payments
$60,248
Ownership & investment interest
$0
Research they led as principal investigator
$7,885,584
Through program year 2024, Craig Laforce of Raleigh, NC is reported in the CMS Open Payments database as having received $14,108 across 29 general payments and $60,248 in research payments paid to them. Separately, studies naming them as principal investigator received $7,885,584 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 91st percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $4,250 | 5 | |
| 2024 | Research | $5,000 | 1 | |
| 2023 | General | $921 | 12 | |
| 2023 | Research | $22,530 | 2 | |
| 2022 | General | $3,639 | 8 | |
| 2022 | Research | $32,522 | 2 | |
| 2021 | General | $327 | 1 | |
| 2021 | Research | $195 | 1 | |
| 2019 | General | $4,971 | 3 |
Beside peers
- Craig Laforce
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Craig Laforce were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.
Show as a table
| Year | Craig Laforce | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,971 | $594 | $163–$1,512 | $163 |
| 2020 | $0 | $426 | $106–$1,233 | $114 |
| 2021 | $327 | $638 | $157–$1,708 | $132 |
| 2022 | $3,639 | $790 | $205–$1,961 | $149 |
| 2023 | $921 | $852 | $220–$2,147 | $160 |
| 2024 | $4,250 | $865 | $203–$2,267 | $164 |
| 2025 | $0 | $1,140 | $272–$2,892 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
35 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy & Immunology in North Carolina
Maeve Oconnor
Allergy & Immunology · Charlotte, NC
Joel Hartman
Allergy & Immunology · Winston Salem, NC
Cristine Radojicic
Allergy & Immunology · Durham, NC
Scott Commins
Allergy & Immunology · Chapel Hill, NC
William McCann
Allergy & Immunology · Asheville, NC
Aerik Williams
Allergy & Immunology · Salisbury, NC
Related records
Allergy & Immunology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.